← Oncology Approval Tracker

FDA DECISION ·

Enoby

denosumab-qbde · Hikma Pharmaceuticals USA

Biosimilar approvalBiosimilarBone loss during cancer hormone therapy
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Prolia biosimilar with oncology uses for increasing bone mass in men at high fracture risk on androgen deprivation for nonmetastatic prostate cancer and women at high fracture risk on adjuvant aromatase inhibitors for breast cancer.

LAMPGEN ANALYSIS

Why it matters

This denosumab presentation adds a biosimilar option for bone loss associated with specific breast and prostate cancer hormone treatments.

What research teams should watch

Establish a supply transition date and keep visit schedules and medication traceability intact across the change.

PRIMARY RECORDS

Sources